<SEC-DOCUMENT>0001558370-21-015503.txt : 20211110
<SEC-HEADER>0001558370-21-015503.hdr.sgml : 20211110
<ACCEPTANCE-DATETIME>20211110161921
ACCESSION NUMBER:		0001558370-21-015503
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211110
DATE AS OF CHANGE:		20211110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Olema Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001750284
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300409740
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39712
		FILM NUMBER:		211396934

	BUSINESS ADDRESS:	
		STREET 1:		512 2ND STREET, 4TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94107
		BUSINESS PHONE:		(415) 651-3316

	MAIL ADDRESS:	
		STREET 1:		512 2ND STREET, 4TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94107
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>olma-20211110x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/10/2021 8:13:22 PM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: 99773224-68b1-4a82-9d19-8cbfce58e8f9 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:olma="http://www.olma.com/20211110" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:EntityCentralIndexKey" id="Tc_d-blIivnrUWaH-i2GS9eEQ_2_1">0001750284</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:AmendmentFlag" id="Tc_vEyDVRxK2kyLqTReKf4S8w_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="olma-20211110.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001750284</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-10</xbrli:startDate><xbrli:endDate>2021-11-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:1.0pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt 0pt 6pt 0pt;"><span style="color:#212529;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_f0f26082_cb26_4824_9a97_68fbedb5e552"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#212529;font-size:12pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#212529;font-size:12pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:16pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:DocumentType" id="Narr_YPD7h4LOFUyphM8O9XUOQw"><b style="color:#212529;font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#212529;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)<br />of the Securities Exchange Act of 1934</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-size:9pt;font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_FF01obqNy0ORk9UeG4R7AA"><b style="color:#212529;font-size:9pt;font-weight:bold;">November 10, 2021</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:16pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:EntityRegistrantName" id="Narr_Iu1t1fUJbkakNSzY8y57Iw"><b style="color:#212529;font-weight:bold;">Olema Pharmaceuticals,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><a id="_65c9dbe8_9374_44c2_b9fb_ab4e0d275874"></a><a id="Tc_2EQnXatRa06MpWiKFEFYBQ_2_0"></a><a id="Tc_JW7PfCu4Q0uCOeK17rHAsA_2_1"></a><a id="Tc_JaiZXuxPIUSUDs0qDz4XTg_2_2"></a><a id="Tc_L-768rp8IEGf632igZoHmA_3_0"></a><a id="Tc_CqIYqVXks0S01Rgbdkh3jw_3_1"></a><a id="Tc_sXLhUkKNx0S8Z9tSaIRMpg_3_2"></a><a id="Tc_o8OSwxszkkyB6rMvfmPxrA_4_0"></a><a id="Tc_uzkDe-fqVESPXmi2QHQN_Q_5_0"></a><a id="Tc_fTguQ2Jig0-ZPCdi3oVcaQ_6_0"></a><a id="Tc_xBr_eOIp8EOsj3cm92UuZg_6_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_4VZYxsups0GVWqDKQmw-Fg_1_0"><b style="color:#212529;font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:EntityFileNumber" id="Tc_1gMwOQvYTU2K_-OsCh1mVQ_1_1"><b style="color:#212529;font-size:9pt;font-weight:bold;">001-39712</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:EntityTaxIdentificationNumber" id="Tc_PoCCiHS71kaCBja02iHtJQ_1_2"><b style="color:#212529;font-size:9pt;font-weight:bold;">30-0409740</b></ix:nonNumeric></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr style="height:20.7pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:EntityAddressAddressLine1" id="Narr_gR7POgZhQUqLzGVb3oX5Ug"><b style="font-size:9pt;font-weight:bold;">512 2nd Street</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:EntityAddressAddressLine2" id="Narr_9eQuRobtt06YkOxG64jlww"><b style="font-size:9pt;font-weight:bold;">4th Floor</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:EntityAddressCityOrTown" id="Narr_bj5QCKsGM0CyZ3cL0ydeRw"><b style="font-size:9pt;font-weight:bold;">San Francisco</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_bnOUy84rrEuwHgSLjB2EZA"><b style="font-size:9pt;font-weight:bold;">California</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:EntityAddressPostalZipCode" id="Tc_akw01Yb2oUqm00kio9QPGw_5_2"><b style="color:#212529;font-size:9pt;font-weight:bold;">94107</b></ix:nonNumeric></p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:39.71%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:32.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:27.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#212529;font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:CityAreaCode" id="Narr_l-ugeO-fqUug1SCCUIDYNg"><b style="color:#212529;font-size:9pt;font-weight:bold;">415</b></ix:nonNumeric><b style="color:#212529;font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:LocalPhoneNumber" id="Narr_3n8qaAjSF0aQ-Lp5yexugA"><b style="color:#212529;font-size:9pt;font-weight:bold;">651-3316</b></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">(Registrant&#8217;s Telephone Number, Including Area Code)</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="color:#212529;font-weight:bold;">Not Applicable</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="color:#212529;font-weight:bold;">(Former name or former address, if changed since last report)</b></p><div style="font-family:'Arial','Helvetica','sans-serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;"><span style="color:#212529;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.4pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_qVyusd0FfE2MkCKIz1jcDg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.4pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_5kXdJpepkk2xdDHoCI9bTA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.4pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_SzDipT0p8U-mwnkfsec-BQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:16.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:16.4pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_C21DqNK040i4x5QeCpwsoQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:6pt;margin-top:0pt;"><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><a id="_d3056176_1ba2_4670_8738_084ba44b4c46"></a><a id="Tc_ouUNg1abNk2vFhJBBuVU-A_1_1"></a><a id="Tc_dBvcwTosZEmeJ6KZuTpNQQ_1_2"></a><a id="Tc_L-bpqRoU70iAn1yypAFnIg_2_0"></a><a id="Tc_TNXbuUxV806IXd3fNUfyZA_2_1"></a><a id="Tc_c4uqZn1AKkOLeCn-z70-Aw_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:40.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading</b></p></td><td style="vertical-align:bottom;width:40.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange</b></p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:39.88%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:19.91%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Symbol(s)</b></p></td><td style="vertical-align:bottom;width:40.2%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">on which registered</b></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:39.88%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:Security12bTitle" id="Tc_Lbb2bIw8OU6p6VoIxcH_-w_3_0"><b style="color:#212529;font-size:9pt;font-weight:bold;">Common Stock, $0.0001 par value per share</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:19.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" name="dei:TradingSymbol" id="Tc_ETJoAaItIU-syCZrn7EWTw_3_1"><b style="color:#212529;font-size:9pt;font-weight:bold;">OLMA</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:40.2%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_AZsC0lzneEKFNxxTETzPsQ_3_2"><b style="color:#212529;font-size:9pt;font-weight:bold;">The Nasdaq Global Select Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;"><span style="color:#212529;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="color:#212529;font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_CO22dS8eXUKwVKgTXKmWTw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="color:#212529;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_qBNGBUKie02rHDAf1MlJCA"><span style="color:#212529;font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:6pt 0pt 0pt 0pt;"><span style="color:#212529;font-size:1pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Arial','Helvetica','sans-serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_5fe5c61e_7f85_4427_ae2b_fcba200f67bc"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;2.02</b></span>Results of Operations and Financial Condition.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">On November 10, 2021, Olema Pharmaceuticals,&#160;Inc. reported its financial results for the quarter ended September 30, 2021. A copy of the press release is furnished pursuant to Item&#160;2.02 as Exhibit&#160;99.1 hereto and is incorporated herein by reference.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">The information in this Item&#160;2.02, including the press release attached as Exhibit&#160;99.1 hereto, shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section&#160;11 and 12(a)(2)&#160;of the Securities Act of 1933, as amended, nor shall it be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Olema Pharmaceuticals,&#160;Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Item&#160;9.01</b></p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d)&#160;Exhibits.</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:12.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:1.92%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:85.09%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="olma-20211110xex99d1.htm"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press release, dated November 10, 2021, of Olema Pharmaceuticals,&#160;Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.98%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.92%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.09%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_99c3cbed_908a_4e6d_9fb3_a997353ee306"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk64480706"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">OLEMA PHARMACEUTICALS,&#160;INC</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Dated: November 10, 2021</p></td><td colspan="2" style="vertical-align:top;width:50.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.65%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">/s/ John B. Moriarty,&#160;Jr.</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:47.19%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">John B. Moriarty,&#160;Jr.</p></td></tr><tr><td style="vertical-align:top;width:49.14%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Executive Vice President, Chief Legal Officer and Corporate Secretary</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>olma-20211110xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/10/2021 08:13:36 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="olma-20211110xex99d1002.jpg" alt="Image result for olema logo" style="display:inline-block;height:55.64pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:187.35pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:15pt;font-weight:bold;">Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate Update</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:left;">Completed dose-escalation stage of Phase 1/2 clinical trial of OP-1250 in patients with metastatic, ER+ / HER2- breast cancer</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:left;">Interim </i><i style="color:#0a0a0a;font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:left;">safety, tolerability, pharmacokinetic and initial efficacy</i><i style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:left;"> data from Phase 1 dose escalation to be presented at 2021 San Antonio Breast Cancer Symposium</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:left;">Phase 1b dose expansion to initiate by year-end 2021; Phase 2 to initiate in Q1 2022</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.27;text-align:left;">First planned clinical study in combination with CDK4/6 inhibitor to initiate in Q1 2022</i></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 6pt 18pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">SAN FRANCISCO, </b><font style="font-size:12pt;">November 10, 2021 &#8211; </font><font style="font-size:12pt;">Olema Pharmaceuticals, Inc.</font><font style="font-size:12pt;"> (</font><font style="background-color:#ffffff;font-size:12pt;">&#8220;Olema&#8221; or &#8220;Olema Oncology,&#8221; </font><font style="font-size:12pt;">Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women&#8217;s cancers, today provided an update on recent company developments and reported third quarter financial results for the period ended September 30, 2021.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#8220;Our team has made great progress advancing OP-1250 through the dose escalation portion of our ongoing Phase 1/2 clinical trial and we look forward to presenting interim pharmacokinetic, safety, tolerability and initial efficacy data at the San Antonio Breast Cancer Symposium in December,&#8221; said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. &#8220;We are encouraged by the emerging clinical profile of OP-1250 and plan to initiate Phase 2 monotherapy expansion as well as the first planned Phase 1b combination trial with a CDK4/6 inhibitor in the first quarter of 2022.&#8221;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">&#8220;OP-1250 has the potential to be a differentiated, best-in-class complete estrogen receptor (ER) antagonist (CERAN) that we believe could become the backbone endocrine therapy of choice for ER+ breast cancer. As we enroll more patients, we look forward to generating additional clinical data in support of OP-1250&#8217;s use both as monotherapy and in combination with other approved breast cancer treatments,&#8221; continued Dr. Bohen.</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Recent Corporate Highlights </b></p><div style="margin-top:14pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Completed dose escalation in the ongoing Phase 1/2 study of OP-1250 in patients with metastatic, ER+ / HER2- breast cancer. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Selected the OP-1250 starting dose and initiated preparations for the first planned combination study with a CDK4/6 inhibitor.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Presented new nonclinical data on OP-1250 </font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">at the 1</font><sup style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial','Helvetica','sans-serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:left;vertical-align:top;">st</sup><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">&#160;JCA-AACR Precision Cancer Medicine International Conference held virtually from September 10-12, 2021 (U.S.) </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="olma-20211110xex99d1002.jpg" alt="Image result for olema logo" style="display:inline-block;height:55.64pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:187.35pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">and September 11-12, 2021 (Japan). The poster presentation reviewed </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">a series of nonclinical assessments Olema conducted on a panel of antiestrogens with known chemical structures to evaluate their ability to inhibit ER activity, block breast cancer proliferation and degrade ER receptors.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Presented a Trials-in-Progress poster at the </font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held virtually from October 7-10, 2021. The poster </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">reviewed </font><font style="background-color:#ffffff;color:#0a0a0a;font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">the design of Olema&#8217;s ongoing Phase 1/2 open-label, first-in-human, multicenter, dose-escalation and dose-expansion study evaluating OP-1250 monotherapy in adult subjects with recurrent, locally advanced or metastatic ER+ / HER2- breast cancer (NCT04505826).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Expanded Olema&#8217;s operational footprint with the opening of new office space in Cambridge, Massachusetts.</font></td></tr></table><div style="margin-top:14pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Anticipated Milestones</b></p><div style="margin-top:14pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Present interim Phase 1 monotherapy dose escalation data at the 2021 San Antonio Breast Cancer Symposium.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Initiate dose expansion by year-end with up to two doses. Each cohort will enroll approximately 15 patients with measurable disease, and findings will help inform the selection of a recommended Phase 2 dose (RP2D).</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Initiate Phase 2 in the first quarter of 2022. Preliminary anti-tumor efficacy will be assessed across three cohorts: patients with measurable disease (N=50), patients with non-measurable disease (N=15) and patients with CNS metastasis (N=15). </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Initiate the first Phase 1b clinical trial of OP-1250 in combination with a CDK4/6 inhibitor in the first quarter of 2022.</font></td></tr></table><div style="margin-top:14pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Financial Highlights</b><font style="display:inline-block;width:227.84pt;"></font><font style="display:inline-block;width:118.95pt;"></font></p><div style="margin-top:11.25pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:11.25pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Cash, cash equivalents and marketable securities as of September 30, 2021 were $306.0 million. Olema anticipates that this balance of cash will be sufficient to fund operations through the end of 2023.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:11.25pt;margin-top:11.25pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Net loss for the quarter ended September 30, 2021 was $17.7 million, compared to $7.8 million for the same period of the prior year. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:11.25pt;margin-top:11.25pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><a name="_Hlk86230375"></a></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Research and development (R&amp;D) expenses were $12.5 million for the quarter ended September 30, 2021, compared to $4.7 million for the same period of the prior year. The increase in R&amp;D expenses was primarily related to the advancement of the ongoing Phase 1/2 clinical trial of OP-1250, increase in nonclinical development activities, higher personnel-related expenses and higher non-cash stock-based compensation expenses.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="olma-20211110xex99d1002.jpg" alt="Image result for olema logo" style="display:inline-block;height:55.64pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:187.35pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:11.25pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">General and administrative (G&amp;A) expenses were $5.2 million for the quarter ended September 30, 2021, compared to $3.2 million for the same period of the prior year. The increase in G&amp;A expenses was primarily related to an increase in personnel, public company-related expenses, other corporate costs and higher non-cash stock-based compensation expenses.</font></td></tr></table><div style="margin-top:11.25pt;"></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About Olema Oncology</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women&#8217;s cancers. Olema&#8217;s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is based in San Francisco and has operations in Cambridge, Massachusetts.</font></p><p style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Forward Looking Statements</b></p><p style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Statements contained in this press release regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;goal,&#8221; &#8220;estimate,&#8221; &#8220;potential&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the development of OP-1250, including timelines related to data presentation, trial initiation and advancement, and enrollment, the beneficial characteristics, safety, efficacy and therapeutic effects of OP-1250, as well as the sufficiency of our financial resources. Because such statements deal with future events and are based on Olema&#8217;s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, the risk that Olema&#8217;s ongoing or future clinical studies in humans may show that OP-1250 is not a tolerable and effective treatment for breast cancer and other risks and uncertainties affecting Olema, as well as those discussed in the section titled &#8220;Risk Factors&#8221; in Olema&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 to be filed on November 10, 2021 and future filings and reports that Olema makes from time to time with the United States Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.</font></p><p style="background-color:#ffffff;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="olma-20211110xex99d1002.jpg" alt="Image result for olema logo" style="display:inline-block;height:55.64pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:187.35pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Olema Pharmaceuticals, Inc.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Condensed Consolidated Balance Sheets Data</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">(in thousands)</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:67.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30,&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">(Unaudited)</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">(Audited)</i></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:67.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Cash, cash equivalents and marketable securities</p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">$ 305,954</p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">$ 338,549</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:67.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Total assets </b></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$ 309,795</b></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$ 342,722</b></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:67.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Total liabilities</p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">$ 8,901</p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.91%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">$ 4,585</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:67.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">$ 300,894</p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">$ 338,137</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:middle;width:67.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#8217; equity</b></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$ 309,795</b></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:3.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#ffffff;vertical-align:middle;white-space:nowrap;width:14.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$ 342,722</b></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="olma-20211110xex99d1002.jpg" alt="Image result for olema logo" style="display:inline-block;height:55.64pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:187.35pt;"></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Olema Pharmaceuticals, Inc.</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Condensed consolidated statements of operations and comprehensive loss</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:12pt;font-style:italic;">(In thousands, except share and per share data)</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.47%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:24.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 12,523</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 4,673</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 35,125</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,415</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 5,239</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,195</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 14,609</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 3,982</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 17,762</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 7,868</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 49,734</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 11,397</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (17,762)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (7,868)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (49,734)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (11,397)</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 105</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 23</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 333</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 59</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (653)</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Other income (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (56)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (57)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 1</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Total other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 49</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 24</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 276</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (593)</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (17,713)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (7,844)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (49,458)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (11,990)</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="color:#231f20;white-space:pre-wrap;">     Repurchase and retirement of Series A and Series A-1              convertible preferred stock</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 4.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="color:#231f20;">(1,869)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 5.5pt 0pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="color:#231f20;">(1,869)</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="color:#231f20;">Net loss attributable to common stockholders</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">(17,713)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="color:#231f20;">(9,713)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="color:#231f20;">(49,458)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="color:#231f20;">(13,859)</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="color:#231f20;">Net loss per share attributable to common stockholders, basic and diluted</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="color:#231f20;white-space:pre-wrap;"> (0.45)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="color:#231f20;">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="color:#231f20;white-space:pre-wrap;"> (3.71)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="color:#231f20;white-space:pre-wrap;"> (1.25)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="color:#231f20;">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"><font style="color:#231f20;white-space:pre-wrap;"> (5.29)</font></p></td></tr><tr><td style="vertical-align:bottom;width:47.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="color:#231f20;">Weighted average shares used to compute net loss per share attributable to common stockholders, basic and diluted</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 39,607,745</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,617,543</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.29%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 39,450,655</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 2,617,543</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Arial';font-size:8pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">Total operating expenses includes the following non-cash stock-based compensation expenses:</font></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:20.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;width:18.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#231f20;font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><font style="color:#231f20;">&#160;&#160;&#160;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#231f20;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#231f20;font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">Research and development</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#231f20;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 2,405</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#231f20;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 392</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#231f20;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 6,427</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="color:#231f20;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 495</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">General and administrative</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 1,752</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 190</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 4,859</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 241</font></p></td></tr><tr><td style="vertical-align:bottom;width:56.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 4,157</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 582</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;">&#160;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 11,286</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="color:#231f20;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><font style="color:#231f20;">$</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="color:#231f20;white-space:pre-wrap;"> 736</font></p></td></tr></table></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;"># # #</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Contact</u><font style="font-size:12pt;">:<br>Eva Stroynowski</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Vice President, Communications and Investor Relations</font></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">eva@olema.com</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>olma-20211110xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 olma-20211110xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $I ^@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBL'Q!XGLM BQ(?-NF&4@4\_4^@H U[FZ@
ML[=I[F5(HD&6=S@"O/\ 7?B"SEH-'38O3[1(.3_NCM^/Y5RNKZW?ZU<>;=RY
M4?<B7A$^@_K6;3L(DGN)KJ9IKB5Y9&ZN[9)_&HZ**8!112H-SJ ,DGH* /<-
M!7;X?TX$$'[-&2#Z[16E4%M$(;6&$=(T"?D,5/4C"O$?$K!O$E^0<CS2*]M)
MP"?2O"=6D\[6+V0=&G<C\S30%.BBBF(]3^'"E?#DI/\ %<L1_P!\K785S/@2
M+RO"L#8QYCL_ZX_I735(PKR_XCL3K<"]A#Q^=>H5Y1\0W#>)0H/W85_F:: Y
M.BBBF(*U]'\2:EHK@6TY:'/,,G*'\.WX5D44 >O:#XNT_6@L+'[-=GCRG/WC
M_LGO_.NEKY\!(((."*[3P[X[GLREKJA::WZ+-U=/K_>'ZTK#/3Z*@M[B&Z@2
M>"19(G&5=3D&IZ0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445Q'C#Q>+!7T[3I ;HC$DH
M_P"67L/]K^5 $OBKQG'I8>ST]EDO>C/U6+_$^U>9332W$SS32-)(YRSL<DFF
M$EF+,22>23WI*8@HHHI@%%%% !6IX<LS?>(K&#&090S#_9')_0&LNNV^'&G^
M;J=Q?,ORP)L4G^\W_P!8'\Z0'IM%%%(95OIUM;"XG;[L<;,?P%>#LQ9BQZDY
M->O>-[S[)X8N%!P\Q$0]\]?TS7D%-""BBI((VFGCB099V"@>II@>S^%[?[-X
M9T^,=X@__?7S?UK8J&&)8+>.%?NQH%'T Q4U2,*\;\:3>=XJO.<A"%'Y#_&O
M8F(523T S7A6K3_:=7O)LY#3,0?;/%- 4Z***8@HHHH **** -OP]XDN] N1
ML)DM6/[R$G@^X]#7K.F:I::O9K=6D@=#U'=3Z$>M>%UJ:%KMUH5\)X#E#Q)$
M3PX_QI >WT5GZ5JMKK%BEU:OE3]Y3U4^AK0I#"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Q]?UB'0M,
M>Z?#2GY8H_[S?X=S0!E>,?$PT>W^QVC WLHZ_P#/)?7Z^E>5,S.Q9B69CDDG
M))J6YN9KRYEN)Y"\TK;F8]S4-,04444P"BBB@ HHHH .O%>R^$]+_LK0+>)U
MQ-*/-D!]3V_ 8%>=^#M%.L:TAD7-M;XDE]#Z+^)_0&O8J3&%%%12R+#$\LA
M5 6)/84@/.OB/J'F7EKIZGB-?,<>YX']?SKAJO:QJ#:IJUS>-G]ZY*CT7H/T
MJC3$%;W@VR^V^)[12#MB;S6/IMY'ZXK!KT3X;6&V.[U!A]XB)#^K?^RT,#OZ
M***0S/UB[%CH]W<G'[N)B/<XKPRO4_B'??9]"6V4_-<2 $>PYKRRFA!1113
M**** "BBB@ HHHH U_#^OSZ%?B5"7@?B6+/##_&O8[.\AO[.*ZMW#Q2+N4UX
M+75^#/$9TJ\^QW+G['.V.3Q&WK]/6DP/6****0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***CDECB7=(ZHOJQP* )**S)-?TB(X;5+,'T\Y2?YU#_
M ,)7H6<?VI;_ /?5 &S169'K^D2G"ZI9D^GG*#_.KT<L<R[HG5U]5.10!+11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHH :S!5+,< =37&:SJ1O[G:A/D1G"^_O5[7M6W[K2!OE!Q(P[^U<]0 4444
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MH_X6!H7_ #TG_P"_1KR6BBPCVS1_$%AKAE%DTA\O&[>F*U20H))  Y)->:>
M[^WTRVU*[NI D**N3ZGT'J:R_$/BZ]UMVB1C!9YXB4_>_P!X]_Y46&=WJ7C?
M2-/9HUF-S*."L R!_P "Z5SL_P 2YB3]GTV-1V,DI/Z "N$HHL([4?$K4<C=
M8VI'<#</ZU>MOB8A(%WIK*.[129_0@?SKSRBBP'LVF>*M)U5E2"Z"3-TBF&Q
MOH.Q_ UNU\^5UGAWQK=:=(EMJ#M/9GC<>7C]QZCV_P#U46&>KT5##-'<0I-"
MZO&XW*RG((K \2>*[;0T\E )KQAE8L\+[M_A2 WKBY@M(6FN)DBC7J[L !7+
MW_Q!TJU8I;+-=L.Z#:OYG_"O.=3U>^U:X,U[.TA_A7HJ^P':J-.P'=S?$NZ)
M_<Z="@_VY"W\L5"/B5J.?FL;4CV+#^M<51181Z);?$R(N!=::ZCNT4H;]"!_
M.NATSQ7I&JLL<-T(Y3TCF&QC[#L?P->-446 ^@Z*\E\.^,[O2G2"[9KBSZ88
MY:/Z'T]J]3M;J&]MH[BWD62)QE64]:0R>BBB@ HHHH **Q->\2V.@PYG;S)V
M&4A0_,?<^@]Z\RUCQ5J>LLRRS&*W/2"(X7'OZ_C0!Z3?^+M%TXE9+Q9)!UC@
M^<_IP/SKG[GXF1!B+73G8=FED"_H ?YUYW13L([4_$K42WRV-J!Z$L?ZU-%\
M2[I<>=IL+^NR0K_,&N$HHL!ZE9?$32;@A;F*>U)_B(WJ/Q'/Z5TUI>VM_")K
M2XCFC/\ $C9__57@]6+*_NM.N!/9SO#(.Z'K]?4?6BPSWEF"*6/0#)KF/^%@
M:%_STG_[]&J6@>-(]5A-G>[8;PH0KCA)#C]#[?\ ZJ\R/6BP'K7_  L#0O\
MGI/_ -^C1_PL#0O^>D__ 'Z->2T46$>N1>.]#FE2)))]SL%&8CU-%>5V'_(1
MM?\ KJG\Q10,ZGXD2[_$$$?9+8?F6;_ZU<=73>/F+>*YQ_=C0?\ CN?ZUS-
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M@>UL+B1#T<(0I_$\4 9]%;$WA?7;<%GTRX(']Q=_\LUDNCQN4=65U."K#!%
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M?RK#GN9KF3?/(SMZL>E &[?^)2<QV2X'_/1AS^ KG)0)Y&DF D=NK,,DTM%
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M=_RS)0?05X_7J7PY?=H4J?W9328%7XE_\>5A_OO_ $KS>O2/B7_QY6'^^_\
M2O-Z$ 4444P.Y^&L2MJ-Y(?O+& /SYKTJO./AG_Q]WW_ %S7^=>CU+&%%%%
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M_P#P@?A__GUD_P"_S?XUJ:7H]GH]NT-E$41CN(+%N?QHN,Y7XE_\>5A_OO\
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M$@PJBGQQI#&L<:*B*,!5& !4M(84444 %>9?$K_D+6G_ %Q/\Z]-KS+XE?\
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MP_"NS\2ZLNBZ/+<@CS6^2(>K'_.?PKQAW:21G=BS,26)[FF@&T444Q!1110
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M_31B_P"A.*+@>0VUK<7DHBMH))I#_#&I8_I76:3\/;ZY*R:E(+2+^XN&D/\
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M60)&C.[<!5&2?PKK-$\!ZA?,LNH9L[?KM/\ K&'L.WX_E7I%IIUG8+MM+6&
M'KY: $_4]ZNT7&9MKIMII6FM;6<0CC"'/JQQU)[FO#CUKZ#J+[/#_P \8_\
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M[T =6+JW+;1/$6] XS4]<N?"SJF5NU+>A3 _/-5X;N^T.Y$,^6B_N$Y&/5:
M.PHJ.&9+B%98SE6&0:DH ***Q=9U<V2B& @SMR3UVC_&@#6>1(US(ZJ/5CBF
MI/#*<1RQN?\ 98&N6M]%OM0_?W$I0-W?)8_A4DWAJXB7?;W"R,.<$;3^')H
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M ?+!PTK\(OX_X5WND_#_ $^RVR7SF\E'.TC:@_#O^-=;'&D4:QQHJ(HP%48
M_"E<9S>@>#;#1]LTH%S=CGS''RJ?]D?UKJ:**0!1110 4444 %%%% !1110
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M*=P,GX;C_BG9_P#KZ;_T!*[&BBD 5S^L^%;/7+V*XNY9@(UVA(R!GZFN@HH
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M)*GW6Q^AK3HH Y".35])_=[',8Z KN7\#3FU76+X>7%&5W<'RHR/U/2NMHH
MP-&T9K9Q<W6#-_"HYV_7WK?HHH **** ,3Q'%)+9QB-&<^9T49[5:T5&CTR)
M74JP[,,&M&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>olma-20211110.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/10/2021 8:13:26 PM-->
<!--Modified on: 11/10/2021 8:13:26 PM-->
<xsd:schema targetNamespace="http://www.olma.com/20211110" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:olma="http://www.olma.com/20211110">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.olma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="olma-20211110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="olma-20211110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>olma-20211110_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/10/2021 8:13:26 PM-->
<!--Modified on: 11/10/2021 8:13:26 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>olma-20211110_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/10/2021 8:13:26 PM-->
<!--Modified on: 11/10/2021 8:13:26 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="olma-20211110.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.olma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.olma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_637721720061041753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637721720061041753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_637721720061041753" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_637721720061041753" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637721720061041753" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637721720061041753" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637721720061041753" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637721720061041753" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637721720061041753" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637721720061041753" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637721720061041753" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_637721720061041753" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_637721720061041753" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637721720061041753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_637721720061041753" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637721720061051763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_637721720061051763" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637721720061051763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_637721720061051763" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637721720061051763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637721720061051763" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637721720061051763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_637721720061051763" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637721720061051763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_637721720061051763" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637721720061051763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_637721720061051763" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637721720061051763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637721720061051763" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637721720061051763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637721720061051763" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637721720061051763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637721720061051763" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637721720061061801" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_637721720061061801" order="24" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>olma-20211110x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="olma-20211110.xsd" xlink:type="simple"/>
    <context id="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001750284</identifier>
        </entity>
        <period>
            <startDate>2021-11-10</startDate>
            <endDate>2021-11-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Tc_d-blIivnrUWaH-i2GS9eEQ_2_1">0001750284</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Tc_vEyDVRxK2kyLqTReKf4S8w_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_YPD7h4LOFUyphM8O9XUOQw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_FF01obqNy0ORk9UeG4R7AA">2021-11-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_Iu1t1fUJbkakNSzY8y57Iw">Olema Pharmaceuticals,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Tc_4VZYxsups0GVWqDKQmw-Fg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Tc_1gMwOQvYTU2K_-OsCh1mVQ_1_1">001-39712</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Tc_PoCCiHS71kaCBja02iHtJQ_1_2">30-0409740</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_gR7POgZhQUqLzGVb3oX5Ug">512 2nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_9eQuRobtt06YkOxG64jlww">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_bj5QCKsGM0CyZ3cL0ydeRw">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_bnOUy84rrEuwHgSLjB2EZA">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Tc_akw01Yb2oUqm00kio9QPGw_5_2">94107</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_l-ugeO-fqUug1SCCUIDYNg">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_3n8qaAjSF0aQ-Lp5yexugA">651-3316</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_qVyusd0FfE2MkCKIz1jcDg">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_5kXdJpepkk2xdDHoCI9bTA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_SzDipT0p8U-mwnkfsec-BQ">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_C21DqNK040i4x5QeCpwsoQ">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Tc_Lbb2bIw8OU6p6VoIxcH_-w_3_0">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Tc_ETJoAaItIU-syCZrn7EWTw_3_1">OLMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Tc_AZsC0lzneEKFNxxTETzPsQ_3_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_CO22dS8eXUKwVKgTXKmWTw">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ"
      id="Narr_qBNGBUKie02rHDAf1MlJCA">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140572479164008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 10,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Olema Pharmaceuticals,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-0409740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">512 2nd Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-3316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OLMA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001750284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M /_/M;;[@CO=%Q]G^E\!4$L#!!0    ( &F":E.?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M6@L5!K!O<B )+LF5&U)=Z7FFMW>3>TFH=>Y!L/?P&HT=S8\?M_P!4$L#!!0
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ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( &F":E,'04UB@0   +$    0
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MMPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !I@FI3EXJ[',     3 @
M"P              @ &3#P  7W)E;',O+G)E;'-02P$"% ,4    " !I@FI3
M'#AEZC\!   \ @  #P              @ %\$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ :8)J4R0>FZ*M    ^ $  !H              ( !Z!$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ :8)J4V60
M>9(9 0  SP,  !,              ( !S1(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  %Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="olma-20211110x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.olma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="olma-20211110x8k.htm">olma-20211110x8k.htm</File>
    <File>olma-20211110.xsd</File>
    <File>olma-20211110_lab.xml</File>
    <File>olma-20211110_pre.xml</File>
    <File>olma-20211110xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "olma-20211110x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "olma-20211110x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "olma-20211110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "olma-20211110_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "olma-20211110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "olma",
   "nsuri": "http://www.olma.com/20211110",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "olma-20211110x8k.htm",
      "contextRef": "Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.olma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "olma-20211110x8k.htm",
      "contextRef": "Duration_11_10_2021_To_11_10_2021_xsfkr2eKF0CZYkudy7UeEQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.olma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001558370-21-015503-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-015503-xbrl.zip
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MEFH!B9(4/]Y-OSMRWIB+)Z9-8[^>J3S6C,8+^80W&#BF@RA)HT'JG3+&PQX
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M:\%&CBGPW\].8B#!!@J]8'[IY7B?/'X?\ZGSA="K]_-Q#,^()9B2ZYI7;]0
MD9!&F RO:]/$"9(0X]K[FQ]_N/K)<;[>?6E#1,/I&!$.(4,!1Q',,!]!CTXF
M 8%'Q!B.8[AC.!HB@,OZV_KOEXUW=?_"N[P$Q\F=[H)$[$D)I)9^W5M66KDK
M)4WP/-=KN'[#]^!=T[MH^F^A\[A4/HHV!WBW-,;DOZ;\T1>#@@A,DN8\P=>U
M$>>3INO.9K/Z[*).V5#LW_#<KX_M;CA"X\#!).$!"5$-A+Z9I"^V:1CP=+;6
M=I_W6:P,+MSE6$:%_)^C9(Y\R?%\Y\*KSY.HEK<HRWL,HN2R&O'E#NOBW]RL
MN)1N6.?QQ5MTZ:;5FI@X@'SJ@CZ*VV(+TE*3+R;HNH;F')$(R7;35QF-T99V
M9=E=.4MO&A8,8SFQE"F_$4.#S"]1<1(4UH?TV8T0EN]T0VXX<L-I>/GD_2Q>
M^M:B@NC;?L)9$'+EEZ:XKNGJ<E+VFFEWV;LTNV7%  $+U6!B<\=\Y HWI(*O
M"7=21[7[@-&QOM5L.*HI?HO[\>%9"D$82NB4I=CO_]:N]V^:ZV6/0B$7&$2<
M/[LO:/KF@UI[ A+!/>&8+^"!#"@;I[^3\(\:Z=^KK*/O#YMJJ2=\-?E+98M1
MTP51I*W7+ 5-V^+1G$FWRE'J((9I=$^B#^)(N"5J67<&<&FCE2DKB"S'3=_K
MT=QEMF*)BT :5X9@MJ9^Q#'Z/!WW$=,DUT@L!L\42#%7KEN*F['-0TG+#Y[2
M$3++BAG[@H98'JL)_QR,=:N<068]:_I@1=Z*&JN9,[1Z)'<K5Y"V%;/W("YQ
MV82R]*2QR\4"VZ)3PMFB12,SBKOVLI[,O6(70=VZB]7<[M?YD1@7!GD#Z3!
M&>1#@1RK8K9[P?PA$J<0>("S&Q4[#N1FO?4\[XA:)-D@MIKA73T?2:^PAZ+_
M:4X%;J-(S%V2_]/&!'G&*=%KK4=U2\0BIAJAU8ANZ_=(/'//-VH#I#L\D:I7
MU,V(_@NFPS]///U]\?3/#$__.^"YHK,WHZ>ALR4VGUB/SLBNN2@HSX7,S7A:
M+E>R<Z!2T^UK,2FMY8FH-#\-D.FY\!/K,/J,26B^JC+*SP5-0U MGR7M.4!J
M:OFU2%U>,ZD13H-KAR8\B/_&DZVW  SB<T%5&U(+:D%Y#ICJ&WXM2#-W$/;5
M7M++9?R6H<  9:EL,8:Z(,N/L==JEJ*F;?%0N-)CLW2KEB7YX$K<&5%B_FA'
M([&8*5,@Q56Y;BE;QC8/Y2LUA-2QZOLY?S',.2(M.AY/27Y/*=%D-NDLIFUK
M-(6<5F0I=]M[/12^W!6*MI4!V*4Q#C''9/@H3BL9#G3)M2*+T3.'4MQM*BR%
M;DNCAQ*WL@3E61EN'88DZ$B\?>FS1_*)2/8T&&B/KEO%%N.W.Z3"T*RT%,<]
M&CX42V'MA&O>D)E#ZGXJ0!^29(K8BS#5[7(^L!H#&Y#=T)\'N.:V7PW?;(C3
M4-Q%X52<5RP\O]_#/-9="FLD%E-J"K0\GI?JEE)H;/-0ZE(7H /P_%_ZOX+R
MKPRT'@OD5U^ZBW&?Z@*7ZQ8CIHVB^"H4+85+W^/!9&5ND-E5OG+=S\.1:!P9
MGG4TR"S&:UNP\BJVKK$4MJVM'GQEDIN"<CW%LX[W8\2&@OQ/C,[X2)PT3 *R
M,-Y--ZDM)G&/F,6/.+122[G<I^,C/^10YI"Y0VY?-:9SL4*3!,O;1=F7'\RS
MH9/:#Z@Q8(G.#9W=:)K;/9;+.:RL\R_$5 QE2USXL"!^$)<\\S^0>=7<U%F/
MHR%:D<62R&H03;T>26%N"ZDO"./*$+P5E]V1O/3^& =#3>QRW6+DM%$4:H6B
MI8CI>SP4K:4;2+MUH*[<U<AML27_?$'^4K[WS?]02P,$%     @ :8)J4YKE
M=6B?!   IBD  !4   !O;&UA+3(P,C$Q,3$P7W!R92YX;6S5FEUOXC@4AN]7
MVO_@R5R'?#"%@LJ,*--9H2E35!CM:&]&)C%@;6)'MBGP[]<.,<M'4L*N=EWW
MHDWCD^/WO(]C;)*[3YLT 2^(<4Q)SPD:O@,0B6B,R:+GK+@+>82Q\^GCK[_<
MO7/='_?/CR"FT2I%1("((2A0#-98+,&49ADD8(08PTD"[AF.%PB 3J/5:'?\
MVT;8##H=X+I%IGO(Y964@#QEV CV+8,B*R5=$ 1>X'NA'P;@MALTNV$+C$?[
MR)&4.<>70Q-,_NRJ7S/9*9 %$][=<-QSED)D7<];K]>-=;-!V4)>[P?>C]'C
M)%JB%+J8< %)A!P@X[L\/_E((RARMPXNW\Q8HA,TO7U?E1'J/U>'N>J4&X1N
M,VAL>.P4$E5SC4YTN&K%K\0?U+*+/\M?>" Y=;R\U9'N 7#':(*>T1SDY[IB
MFZ&>PW&:)2I7?F[)T+SGT$1:I@C('U]5\OYS,53TWSZ)'XC 8CLD<\K2W$<'
MJ/S?GX='6E2N1D133S5Z]?+D==5RS-L5EC'$9;;\\D?96%2CNOSW8@[,0AN!
M2(SB_5DL5 ^^[W=\X *=Z/ 0DACLLH)_5F->H:PQH=&1ED0-7\J.R:ET7.;+
M<W$4-1;TQ8L15O>3KPX45M_U@V*(OI>G?@ZHG#?Z,RX8C(3.E\ 92GK.29OW
MWZO1SDUEWA,QI\T_6\UV.PS:TK!6X'\(VC?- XF'@Z+/CN5"%NG<\O!LG!RC
M*"*\##*9SXV6.-F/@#FCZ9E+14^TIF+*8L3DG.V %9<Z:*84P^1_=7N,&*9R
M^,>?Y9S]BNU'<7;Y?UEZ 2(T 6(W1WS!"?JV2F>(E3 X#;'#_EJJ"^>;YIQ_
M1@NL"B#B&TS+[H"R,)L(U%!>4/A@CL)0+EE91EGNV41:AP9T103;#FA<#>75
MJVQB='TA!;(;<\BF<#.,9<ER!;];3U^8ORKB;<)T30D%H)8Y0/TXEN[QXH]<
M'J.@$DY)K$U@ZLHOH+3?$I3P"BBAW5#*Y1=0;HU#&<C#)S:E:W()R=^1%@*Y
M(+[ T3&.(_\<?&)C1E_P[FN/5YF<A%L(IDX%>L_H&\<SIES Y ^<O;I$*PNV
M$,UE_1J,D=V\NJ7[#,$*%(?-=IA_4;&VV\B>77V#G(R7E%3OV4]#[+"]EFIM
MO9%-^^\,"X'(@*;IBA2K<%[B?VF<'1#J2]<DC&S<)S3!$1:8+$;R8XMAU>T9
MAO.@XT)N@G;K+3*HJ5L#,+(-'S.DQ@B22X7\:V;UA((]S>>E\U%UL!U KM2O
MP1C9?I]H'7*^0NPJ/&>76 FI7A4:E9%-^01%*SG=;H-P-E7/],JFL),0.U#4
M4JVM-[+UGC*H7E*8;-,9+?OH.&JWP_3+DK7C1G;7>DP\;*(E) M4\<"C+,P.
M_VLKUP_\#.ZB'U+$%G*P_,;H6BSEM)E!LJW<1I=&VP'EV@(T&R,;Z4+L1M[)
MA&/5\>[I<368LU"KJ-13KY$8?$ ^D$4RF SE6F+S%57?*"=Q-L&H(UV3,++W
M[LM%7:P6=E\2N"@A<-1^++\5W/K!&W3^LF3M>-4>^\X[?0E-O;'H[;S!NW>Y
M/OX%4$L#!!0    ( &F":E,*YWU$S!4  'N6   4    ;VQM82TR,#(Q,3$Q
M,'@X:RYH=&WM/>M3FTZ[W\_,^1_V^#OO6SLC! BY$*WOQ!@U51/-Q5J_9!98
M$AH"N(!)^M>?9[DDY.(]VMACIZT"R^X^]\L^N^S]9SRTT!VAGNG8W[Z(O/ %
M$5MS=-/N??O2:1]QQ2__V?\O!'_"_Q#:^Q^.0^;U0?,,Z8X6#(GM(XT2[!,=
MC4R_7T)MQW6QC<X)I:9EH0-JZCT2OZ+P>;Z@"$5>RHJ*@CAN/]WM ?:@%\<N
MQ:U%7EQL4HF'8HU$,2,*&4F01%0LB=F2)*&+\\47HI[.3)5B.DD@A7=Y(9F(
M)!16O]0B],[4"/KNJ*AV6$**4BAD)4GF\D55Y&1<E#A%%Q6NJ*F&1G)%4C32
M(,&/O;X/Z 44VUY))^:WK;[ONZ5,9JQ2B_>(QO><NPP\8$ (G"!R67$K;NY8
M0SQM/QJ->':#UYQA"##\$>*6<XU&6=ZAO0S@5LF,V>!)=Y9I#^9:AE-@;25!
MR&;88Q6PGS0?+[6?ZYD]G3:%CG1_'K2XWUPF>CAMNG*RT%#,7)^?M;0^&6+.
MM#T?V]IT*N;8YP!5<V\FJ#-MF EAQ,KX%-N>X= A]H' T*F8XX1B"J'0SVH$
M/-:)Q$GY62?W(5',ICI*FE-BW(OT? :>II%H/D"?*5+V]_H$Z_M[0^)CQ)IS
MY#8P[[YM:8[M@RQR_L0%U,57W[9\,O8S$2-D]O=\T[?(_EXF^1GUI3KZ9']/
M-^^0YT\L\FUKB&G/M#G?<4M9P?5W8=0,/)YKHYN>:^%)R79LPAJ8XQ+KC=#H
M5U/7B1W^"@WJH":HJ46S&OM-AI7#@(9([HIB5Q2ZC*F[;2=]-?:, 97(Z9%0
MN?DY"/1)H4.JEUO(QD,V/C%+51L F50 4(JMFJV3\2F9;"%3_[;5UKHZIUHU
M\\ZFG1_XA#.EXY8"[W>EKKBU+P#/%7*"5)3W,G-S?.LIET%AZDQI'EFX-YWJ
M775R>-4<GTJ#R=EMNTE.#;E5''6S;*H&MCRR-,O,/)*!E0@%Q4V\_3TFG"4O
M%":8-@J%M=0/69'I$"[1'_S8T[?BQXQKOFUYYM"U&(]EYON(ADN/$5YZ3D##
MJY![2S&J0IA>C*JD,Q*2-KDR=79MF(2B<%)DI3:HU$[G*;OX\GYR:[YW%U#J
MZ,D5"!KU#\'([+-Y<B+\%9+W9L^FT]3O:9H\2:Z303)SR$HP.T5E)B5'2S(W
MQ&-N9.I@9$5!^->NBW5FISF+&#[<X;.YV3UJ]OJSFXYG,FK 0!:0Y2X4V%2_
MFD4P+:F.W]]='&+IS2$HACZ)>A?Y7*0=W*0G \#B##PTK4GI2YF:V/JR\^6$
M6'?$-S4,OWN@8$&=4]/XLALV]LS?!,:"?M(]\^Q& @M,S'>&)3%UBZDF=LUP
MR&'+[-DE#8A*Z*[J4$#>[)TQ\AS+U-$_0O@G>1[J-C;*PN-(]978 _8O'_UD
M,'K,J4D0YE@.+?TCB5).4M)P0-/P:A3!H3J6OGMG>J9J6L!PL<1";__^IR@)
MV=V]#.L5*.WN[^%0<+J&8$AYH2AU-57*=^6B)'<5K!2Z^:*A$EW-D5Q.8A**
MUX3U90S.4,# 5A^%65H%]-9^IUYK5P]1JUUN5UM[&36"<K/GW*I6.LU:NU9M
MH7+]$%6O*R?E^G$551KGY[56J]:HKPT0Y1$X%MGO(9CF@?B!O3[(B._8.^B0
MK_!($G*RLCX*Y-]LYD>-YOF__Q'SPFXXV[>UQ(=Q]-(.'28F>W5,:??GQ6&A
M+Y\UCCH3MW]>;"C7G<;EZ%E@%+G3"-N+-MN=T[HOEH!0.<8^6JSG\HOZ4U3(
M<(7V3JGV>1.@8FW0HTY@ZUP,7ZP0DQZ9\EWJCFE1@<_#4%''4HZ'GB,5&WF&
M"5L@'/C.S)&,_G\7&<J^A!-!#32K]39J5B\:S?8'$/J+@'H!AEC<=R!NU1B9
M(DD2L\BA2,QMZU_W5 I!@&,@OT]8HX ".8F'JF.MCVV(T<N:C^"QJ&3E]U/8
MSX%YBL05&&#>%IM]D[@.]=%V<@VNC050^HC<L5P%#1\3_6L)O9F2B2+(;UL0
M<I9TF,80>NWK>#*!N1![E1*Z"+W#:N0SIK31T9$@.NIM?2(TF@.E0X[E9J%<
M?@66ZLX=&:K@1XO"#F) W*NIWL=.I*3S/6+%)NF9'HOR_3H\22&Z%HB^:'2^
MJP,\J+=^_RQ.<H7:\]1^PX)H"5WT,1!?(P%#CN7M1%)8LS7^S3#]=EIENSK&
MH!,8%IDHT2GV$/:0YQ*-A54Z,FUD^AX"+0*21;].=<>GL5NCL1-GB"BM"$EF
M#?,K$?:\*"2?TQ1=)<6NDBW(75G6I*ZJ&&H7JS(1=*F0*Q;D. K!21)#JE[:
MU]AO8B%_[OXP3X^J1S\/6+Y%6&SY_4?APJ@$\J405!KD5"S0D[)7CC(S"RVQ
M>7,=C"]JG5;GT!-N#W_+U^T>M)066YYQA7R1NL5:]=C(9R6S=^.<#,O=[/+H
ME=O:S]NKZX$GM 2QV5/U03_[*TZVS+?TKL_ZG<%I?2RTBC>*W\*UYKG;@Y9+
MHSO%1FLT]GX/!I.#/#V_,X878UKNRLNC![\'AX0S;J^JK8OKH2E=GES6NY?=
MW')+H]T++J7O9D_@;BXJNIEUKC1\V<TOMQP?T"YIU-QBM>']RFI#1>H$-SUH
MF<S3QZI%IMP?1<# ^19V/5)*?EG4W;$PL(Q G$Z<SSBD0_0HW<#NS N=3Y-1
M4Z+%[NO)_3M"0TT9*Z^(8^->L@I?$/^59OIXO$0 4C*=ZA],'#4L9Y0P>G+-
MC2AV2RHE>,"-  F/YD5B\1'2Z@"KGF,%_J)V>3?I%I\NRVGMD_'U)V-=X@O2
M)];?&>M2@<_E/[&^-JQG?+I*_0A\<:T:Z%WR66\<H[#E-9;:]HE+G3OF[,T'
M*9'K#"ZL0R%V"L=KL=85\*!\.JDX.IFN9,A7-S_'7N!ZPO'5C]O#T\OAB#OJ
M=<70:+TXM .6'4'H=*\'O4[M]F$INDBP(],B, ($>U/JB+WS4>/R[F>[(YUV
MN897Z8O#JTN@CO@*Z@ALW5HIB-(ZR/.H&OQKR-/&XUJ\,J6%72[0ZL*I5,R3
M5D$<X,K!+RQ(YHG_G=%*>@6ML@(GR()2D(6'B?5!M.=CD>]<M+LJO@WU&$N0
M.7Z?4/0KH*:GFV'Z;!K%;I)R>37 %6<X-#WOA?"]N72^&KX:W^1;/*H.7<N9
M$#H/Y#U<+?*%OXJK'0.9:6/]]:]D96;>4*0S7P3@QO/RO'5 =8?_^A1VEH0-
M8^>-L;AE7:?$\^(?9Z9-Q%0&N-<L7#1Z-_W+SNW9[^,K->M<YSJ])1H]9%US
MHH0D6T<MGQ+BK[2P3^]LY^W6)QY'C)1"C$(N@Z:C^KZ0_SEHC(_S\B]K-'H6
M8F2_CXXLQZ%_CP=_3\0JO2;YNDG:Z\\BX8/XGYNFVBKP:X.VG9&=DE_U5^ZR
M<NH=GPN5R4U6.Q,F.FD^3WY;0.8CBFW-]#1G<_7:LW,:,=K"**!!+Z"E&58>
MSW!G-SJ3HDQI-1B=]%IGOPZDZDWY6;BK &O Q&P3_^W*3_E_I?O>4:PO'.!D
MZ\9TYU)M># 2Q)^JY'1NAX(P,!WE\N)XU,V]*D&@R*)0>%%NX$-'48^OA,>D
M8,O@+@4M8;K80F1,M( ET^$V..K$V\Q0Z]DR_5=(\9H9 ,0/,?E;%81EP@76
MC[+&_SXE74^LNWM(&6V_0P3$7*8R)7BF6D/#;W%!CS0XX[83],16I=*I'?ZL
M]UX!BRSF'G:<GMG?U_<(#\\<$-Z+OF//+22$",K:Q5M<_M4Z$O E=^;F)F0<
M]%Y3F9;/B5PV*^8_8IG4K*R,B9M8V/50FUC$99B+<U0[J&9K5L 4'&+\MJ!+
M-K<4MN[XJ.RZ%HP..NX#E,)N'T$80&A<M4;#J  N<63 =Y!IH*C>%<P4<_>1
MA;VD+O2S=NW-"K5?LK,&HJ<^T09AP3)V(9(#UXLMV*C.&*G$<D:,F.PA(WE4
M:5GD3I$!-A#$S/20R>J6=*"T[P"QAX'E8YLX@6=-D >8\8Q)^'K\@J,"+T;9
MUKA*.E7Q"!AG7&1/DF>&8\$,V'LLQ#39FHJ'MCU"T#&Q"07WL&;#NT&XFN2A
M,B_QT:2_EM+6^&FU63&IA*BH*NUCQ9R2Y_/++M3#[E@H?L 9NZ.^Z1,.IJ01
M8 96.;([[55^(W=TA5C,=IV^8]V#ZCB6BH&2/C!5VO;]H*8/S,,6S ([3L)[
M*0-X>S4)/%TX,JK2^:!R6OLM_M(.>ZL\M@1#+=)S".K44&LR!%VU*"#,5U,*
MLCSSU1Y/%?PIRMR? -C:CQ$']$IC#KFI'0K-P"*1N,I2+I:LA4T);"_"MEA
ME:,FDK("#PV_KDX3)L[WIR!MIB"U'/ =@*AV[QQT-P,N)46YP;7^W27N8""-
M]<,3IU)3U';Y4XKV9UA#PQAM]XB0*&-.E%)2-+>?9RI#LL!'+3_%Z$.*T04E
MS!:Q#?CAMD7FU]"&8<Q%9:W?AZ;;%MQBAQN.[($!/7('EY_BM _8X[04^IYF
MG419YZ1M]6MT]20)BU[XE+&_0<9JGA<0NEK2*I)X>%L_%63!E,>Y2U)Q1Y[S
M*6DOEK0LX>1M[1F2%K_P->TT1N$:H1#PN?=NB)T)=!S(0=>EA^7U8^1UX[U;
M>E;(Y<5"OBNJ6.K*^8+0+1:RQ:Y0E%4LRZJLR?FMQ?U+0:?>$[%:'TAW1_WO
M!P?!58<KQX7!<RWU@SMMU':\F^J0?,^?W@1MMWZ9E*4N[,A2W=NFTRD(9MD6
M)Q.W?&37>JOV@[7KUVK0&5\5A7SM6L\:]8XQN5FY'TR3@]L;6RR?#AIGI&)S
MOPL"5QZE]H-]W)U.Q>+G[H_Y,I)G+#N];,^-J/#*Y_ZR]\8Z*._/[67K0_K:
M2J4>5D#OAHOWJB)Y5/C_=/UOFV(VG9=4%#PF8G\:M'I\H #!6A^1V,5[HUI]
MQM8+AX(]>.[79I<AM-G)C5/4:1;VO)<P2,S\'P8OJVH2PRAJ^V4E-Y& ?&3P
M'1M!" \\,(MYGBA \N;9A3];:Q<'D!-14D/QFE;8G:FJI-9&Q48G[^:OG-I8
M.^ERH_A,B9?6.; $ Q"OY3O:8 ?]K\"S$RN1BRFZPU9 D,L.N>RO:;?KFQNY
M#2!?;"<C?3"E7;7]W2GCFE_K<-ZD<D/M0O5'.SGEXZ6T:YR=E]=!EK>VSQNS
MJYS9]N7BZT3@DN3.["PF(%SYQJL(UF^;5$^/ZN-QN]K^?>%=QH>NO)1P[3Y!
M=>SI^!8=6XZ*+=0B%M%\=([IX)ZM.A\Y%?3G"C9JMLY2?02I$Z2%Q1O0SP!L
M%0EWV"X459@>@JX(8+S'5KIZU!GY?98Q=%FA!?:03@S3CHZ82BT:"SFT?(S=
M[/2Z+-IF#0N[X<)QTM@,3ZARV0E5K"PHE7N45$Y:T>&J<_&F/;,4Y.R]5-_\
MVDLM7W<F;925K=Z#XF2R?S3M'A6[)U,\#F=8B2:8SK@W)$EO%<EUYW1T==IK
M7Y\.0:._/N.>?S#C_A84S+Z$@C7C 5'9 0%9*7?F4AU3'Z0JU'T@5;83YL<#
MCX2M@.1QM10[!S],C:#HW&I&RW L:\(&9Q]Z"$NA;#)BLD0)Z"5X#V25;1("
M]8HUC9T.PAJSD^MU3'4OJI/2'TS.9[?Q?'(^+83\1K'KN#W%4G1\8[HXZ*!^
M?- Y-8D@T9/#LB&>6]\KBV4-*^B]SK6BM7 N^Z(!ERXM?/Q,[OFH:M4AVZDS
MN)</Z(YE)=9RR;^GRHKX)ZWFLVS[DI>R:9,47W.:^726<]^)>-:4TZSWU#D+
M+TJD_O=_/:G"-G5,?K+7/F3_'N&B_#,VP $H86N$)U[LZ1<4/ONOV4I^# /[
MJ@:*#N='J=]G9;<;=NC_UG1Q,6>0G)872;=@%'-=698*74PDM6MH*I8$P<@7
M5"U>BEL+HR[QWX(I97N-5^F'A.VB;[)PJ@71=A01@:&$:"BU@E>05F5;7C/?
ML!_@>+ GUC($J;B,$9&9=I_$U<L2+\3'*(6,VB1>8/GAIK,&&.)X!1W,*3J:
M6MJ* Y:?/>#?P>-LL',H%DX0WD&/G7P[/70Y/"9VYB30&#SF7#!;?QN$!\BB
MR EI$?"GPY&R\4@\*H.M=Z<5V&ZX(P^XE&#P8, '-P)JFUY_P<.81R^+*JKC
M/J@(/[JI*+R((#8AT)2A-BP;3XY/@:[8(P@_P*^:?@'E/5#-0E;3GGZ,B$5
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M4F-096#O8/O=2'4_2SS\#M]Z>$9(TNS#:KO<:F8-<Z6<3.5]ROI!?<HED+Z
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M#3[;,7ER\Q,=3\X_G&+\@OG@;L6ZQ*J;K24FVL29"WS8G''HMGR(^3_7QXZ
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MX482G VX\P0_1M'8N_A_4$L! A0#%     @ :8)J4V^(M;54 P  Y L  !$
M             ( !     &]L;6$M,C R,3$Q,3 N>'-D4$L! A0#%     @
M:8)J4_B5/D6X!0  LT$  !4              ( !@P,  &]L;6$M,C R,3$Q
M,3!?;&%B+GAM;%!+ 0(4 Q0    ( &F":E.:Y75HGP0  *8I   5
M      "  6X)  !O;&UA+3(P,C$Q,3$P7W!R92YX;6Q02P$"% ,4    " !I
M@FI3"N=]1,P5  ![E@  %               @ % #@  ;VQM82TR,#(Q,3$Q
M,'@X:RYH=&U02P$"% ,4    " !I@FI3MDZOK?P?   #Z $ &
M    @ $^)   ;VQM82TR,#(Q,3$Q,'AE>#DY9#$N:'1M4$L%!@     %  4
*30$  '!$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
